Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Novocure Hits Record Revenue & Raises 2026 Outlook
1+ mon, 2+ week ago (423+ words) Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors. Novocure Ltd. has a market cap of US$2.32 billion and 115.82 million shares outstanding. Key near-term…...
Novocure Posts Record Q2 Revenue of US$183.6M
1+ mon, 2+ week ago (892+ words) Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million. An oncology company is catching the attention of life sciences investors after releasing Q2 financial results. The company's 2026 financial guidance has…...
Novatek’s H1 net profit down
1+ mon, 2+ week ago (194+ words) Novatek reported a profit attributable to shareholders of 218.7 billion rubles ($2.78 billion) during the first six months of this year, compared to 225.6 billion rubles in the same period last year. According to Novatek, normalized profit attributable to shareholders, excluding the effect…...
Novatek’s first-half IFRS net profit down 3.1% to $2.8 bln
1+ mon, 2+ week ago (181+ words) MOSCOW, July 24. /TASS/. Novatek’s net profit attributable to shareholders under the International Financial Reporting Standards (IFRS) declined by 3.1% year-on-year in the first half of 2026 to 218.7 bln rubles ($2.8 bln), the company reported. Revenue from sales increased by 3.9% to 836.3 bln rubles ($10.71 bln)....
Russia's Novatek says H1 net profit edges down 3% year-on-year to $2.8 billion
1+ mon, 2+ week ago (35+ words) TradingView Russia's Novatek says H1 net profit edges down 3% year-on-year to $2.8 billion More news from Reuters...
NACLIND: Q1 FY27 saw lower revenue but higher net profit; Nasense Labs stake sale approved
1+ mon, 3+ week ago (76+ words) TradingView NACLIND: Q1 FY27 saw lower revenue but higher net profit; Nasense Labs stake sale approved Revenue and net profit declined year-over-year, but net profit margins improved. The board approved the sale of the Nasense Labs stake, which contributed significantly to prior…...
Nova Releases Q1 2026 Financial Results
3+ mon, 4+ week ago (198+ words) Nova Ltd. (NASDAQ:NVMI) reported Q1 2026 non-GAAP earnings of $2.33 per share, surpassing analysts’ $2.24 forecast and beating expectations by 4.0%. The metrology and process control solutions provider posted revenue of $235.3M for the quarter, up 10.0% from the $213.4M recorded in Q1 2025. Adjusted bottom-line profit came in…...
Nova Reports Record First Quarter 2026 Financial Results
3+ mon, 4+ week ago (596+ words) May 14, 2026, 07:30 ET REHOVOT, Israel, May 14, 2026 /PRNewswire/ -- Nova (NASDAQ: NVMI) today announced financial results for the first quarter, the three-month period ended March 31, 2026. First Quarter 2026 Highlights: Earnings per Diluted Share A reconciliation between GAAP operating results and non-GAAP operating results is…...
Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration
4+ mon, 1+ day ago (25+ words) TradingView Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration More news from Reuters...
NOVANTA INC 1Q 2026: Revenue $257.7M, EPS $0.51— 10-Q Summary
4+ mon, 1+ day ago (184+ words) TradingView NOVANTA INC 1Q 2026: Revenue $257.7M, EPS $0.51— 10-Q Summary NOVANTA INC reported first-quarter 2026 results with revenue of $257.7M, up 10.4% from $233.4M a year earlier, while net income was essentially flat at $21.1M versus $21.2M in Q1 2025 and diluted EPS declined to $0.51 from $0.59. - Revenue was $257.7M for Q1 2026, compared with…...